US4810643A
(en)
|
1985-08-23 |
1989-03-07 |
Kirin- Amgen Inc. |
Production of pluripotent granulocyte colony-stimulating factor
|
US4933447A
(en)
|
1987-09-24 |
1990-06-12 |
Ss Pharmaceutical Co., Ltd. |
Quinoline derivatives
|
US5021409A
(en)
|
1989-12-21 |
1991-06-04 |
Johnson Matthey Plc |
Antiviral cyclic polyamines
|
US6001826A
(en)
|
1989-12-21 |
1999-12-14 |
Anormed, Inc. |
Chemical compounds
|
GB9126677D0
(en)
|
1991-12-16 |
1992-02-12 |
Johnson Matthey Plc |
Improvements in chemical compounds
|
GB9200245D0
(en)
|
1992-01-07 |
1992-02-26 |
British Bio Technology |
Compounds
|
US5235056A
(en)
|
1992-04-22 |
1993-08-10 |
Ciba-Geigy Corporation |
Substituted 1-hydroxy-2,6-diaryl-4-piperidone ketals and polymer compositions stabilized therewith
|
GB9400411D0
(en)
|
1994-01-11 |
1994-03-09 |
Johnson Matthey Plc |
Improvements in chemical compounds
|
US6506770B1
(en)
|
1996-06-06 |
2003-01-14 |
Anormed, Inc. |
Antiviral compounds
|
GB9511357D0
(en)
|
1995-06-06 |
1995-08-02 |
Johnson Matthey Plc |
Improved antiviral compounds
|
WO1997009976A2
(en)
|
1995-09-01 |
1997-03-20 |
Washington University |
Method of reducing neurotoxic injury with zinc chelators
|
CA2249401A1
(en)
|
1996-03-22 |
1997-09-25 |
The Dupont Merck Pharmaceutical Company |
Novel asymmetric synthesis of r-.alpha.-propyl-piperonyl amine and its analogs
|
IL133212A
(en)
|
1997-06-02 |
2005-12-18 |
Janssen Pharmaceutica Nv |
History of use (imidazolil-5-yl) methyl-2-quinolinone that act as culture inhibitors of smooth muscle cells
|
JP2002510327A
(ja)
|
1997-07-25 |
2002-04-02 |
メルク エンド カンパニー インコーポレーテッド |
環状アミンケモカイン受容体活性調節剤
|
ES2255733T3
(es)
|
1997-09-30 |
2006-07-01 |
Daiichi Pharmaceutical Co., Ltd. |
Derivados sulfonilo.
|
GB9726229D0
(en)
|
1997-12-12 |
1998-02-11 |
Zeneca Ltd |
Resolution of chiral amines
|
KR20010032841A
(ko)
|
1997-12-19 |
2001-04-25 |
다케다 야쿠힌 고교 가부시키가이샤 |
아닐리드 유도체를 함유하는 ccr5 길항용 약학 조성물
|
US6607799B1
(en)
|
1998-10-15 |
2003-08-19 |
3M Innovative Properties Company |
Surgical dressing with delivery system and method of manufacture
|
US6635278B1
(en)
|
1998-12-15 |
2003-10-21 |
Gilead Sciences, Inc. |
Pharmaceutical formulations
|
TWI230618B
(en)
*
|
1998-12-15 |
2005-04-11 |
Gilead Sciences Inc |
Pharmaceutical compositions of 9-[2-[[bis[(pivaloyloxy)methyl]phosphono]methoxy]ethyl]adenine and tablets or capsules containing the same
|
US6365583B1
(en)
|
1999-02-02 |
2002-04-02 |
Anormed, Inc. |
Methods to enhance white blood cell count
|
ES2265923T3
(es)
|
1999-03-24 |
2007-03-01 |
Anormed Inc. |
Compuestos heterociclicos que se unen a receptores de quimiocinas.
|
US6245799B1
(en)
|
1999-11-08 |
2001-06-12 |
American Home Products Corp |
[(Indol-3-yl)-cycloalkyl]-3-substituted azetidines for the treatment of central nervous system disorders
|
US6683192B2
(en)
|
2000-03-30 |
2004-01-27 |
Curis, Inc. |
Small organic molecule regulators of cell proliferation
|
PE20020354A1
(es)
|
2000-09-01 |
2002-06-12 |
Novartis Ag |
Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda)
|
NZ524421A
(en)
|
2000-09-15 |
2005-02-25 |
Anormed Inc |
Chemokine receptor binding heterocyclic compounds
|
NZ524651A
(en)
|
2000-09-15 |
2005-08-26 |
Anormed Inc |
Chemokine receptor binding heterocyclic compounds for the treatment of HIV or FIV
|
CA2419224A1
(en)
|
2000-09-15 |
2002-03-21 |
Anormed Inc. |
Chemokine receptor binding heterocyclic compounds
|
CZ20031910A3
(cs)
|
2000-12-11 |
2003-12-17 |
Tularik Inc. |
Sloučenina s antagonistickými účinky na CXCR3 a farmaceutický postředek
|
US6878714B2
(en)
|
2001-01-12 |
2005-04-12 |
Amgen Inc. |
Substituted alkylamine derivatives and methods of use
|
GB0107228D0
(en)
|
2001-03-22 |
2001-05-16 |
Astrazeneca Ab |
Chemical compounds
|
US6794379B2
(en)
|
2001-06-06 |
2004-09-21 |
Tularik Inc. |
CXCR3 antagonists
|
SI1411918T1
(sl)
|
2001-07-31 |
2012-04-30 |
Genzyme Global S A R L |
Postopki za mobilizacijo progenitorskih/matičnih celic
|
US7169750B2
(en)
|
2001-07-31 |
2007-01-30 |
Anormed, Inc. |
Methods to mobilize progenitor/stem cells
|
US8178123B2
(en)
|
2001-08-29 |
2012-05-15 |
Femina Pharma Incorporated |
Method for augmentation of intraepithelial and systemic exposure of therapeutic agents having substrate activity for cytochrome P450 enzymes and membrane efflux systems following vaginal and oral cavity administration
|
CN1272322C
(zh)
|
2001-09-12 |
2006-08-30 |
阿诺麦德股份有限公司 |
对映体纯的氨基取代稠合双环的合成
|
MXPA04006136A
(es)
|
2001-12-21 |
2004-11-01 |
Anormed Inc |
Compuestos heterociclicos que se unen a receptor de quimiocina con eficacia incrementada.
|
US7354932B2
(en)
|
2001-12-21 |
2008-04-08 |
Anormed, Inc. |
Chemokine receptor binding heterocyclic compounds with enhanced efficacy
|
US7491544B2
(en)
|
2002-05-20 |
2009-02-17 |
New York University |
Chiral piperidine and quinucledine ligands
|
DE60325740D1
(de)
|
2002-08-14 |
2009-02-26 |
Silence Therapeutics Ag |
Verwendung von protein-kinase-n-beta
|
US7759336B2
(en)
|
2002-12-10 |
2010-07-20 |
Ono Pharmaceutical Co., Ltd. |
Nitrogen-containing heterocyclic compounds and medicinal use thereof
|
US7291631B2
(en)
|
2003-04-11 |
2007-11-06 |
Genzyme Corporation |
CXCR4 chemokine receptor binding compounds
|
CN101941964A
(zh)
|
2003-04-22 |
2011-01-12 |
阿诺麦德股份有限公司 |
具有促进功效的趋化因子受体结合的杂环化合物
|
US7501518B2
(en)
|
2003-04-22 |
2009-03-10 |
Genzyme Corporation |
Methods of making 2,6-diaryl piperidine derivatives
|
US7498346B2
(en)
|
2003-12-11 |
2009-03-03 |
Genzyme Corporation |
Chemokine receptor binding compounds
|
EP1730113B1
(en)
|
2004-03-15 |
2016-12-28 |
Genzyme Corporation |
Process for the synthesis of a cxcr4 antagonist
|
EP1742936A2
(en)
|
2004-04-13 |
2007-01-17 |
Icagen, Inc. |
Polycyclic pyridines as potassium ion channel modulators
|
DE102004021716A1
(de)
|
2004-04-30 |
2005-12-01 |
Grünenthal GmbH |
Substituierte Imidazo[1,2-a]pyridin-Verbindungen und Arzneimittel enthaltend substituierte Imidazo[1,2-a]pyridin-Verbindungen
|
WO2006020415A1
(en)
|
2004-08-02 |
2006-02-23 |
Smithkline Beecham Corporation |
Chemical compounds
|
KR20070042568A
(ko)
|
2004-08-16 |
2007-04-23 |
스미스클라인 비참 코포레이션 |
화합물
|
JP2008511669A
(ja)
|
2004-09-02 |
2008-04-17 |
スミスクライン ビーチャム コーポレーション |
化合物
|
JP2008514622A
(ja)
|
2004-09-24 |
2008-05-08 |
スミスクライン ビーチャム コーポレーション |
化合物
|
TW200619206A
(en)
|
2004-09-29 |
2006-06-16 |
Anormed Inc |
Chemokine-binding heterocyclic compound salts, and methods of use thereof
|
US20090093454A1
(en)
|
2005-03-04 |
2009-04-09 |
Kristjan Gudmundsson |
Chemical Compounds
|
EP1904645B1
(en)
|
2005-07-08 |
2010-08-04 |
Siemens Healthcare Diagnostics GmbH |
Method for predicting and monitoring direct response to cancer therapy
|
JP2009500451A
(ja)
|
2005-07-11 |
2009-01-08 |
スミスクライン ビーチャム コーポレーション |
ピラノピリジン化合物
|
BRPI0614256B1
(pt)
|
2005-08-02 |
2018-10-16 |
Ineos Europe Ltd |
processo para a produção de homopolímeros ou copolímeros de dienos conjugados
|
US20080234318A1
(en)
|
2005-08-31 |
2008-09-25 |
Kristjan Gudmundsson |
Chemical Compounds
|
JP5217438B2
(ja)
|
2005-11-18 |
2013-06-19 |
小野薬品工業株式会社 |
塩基性基を含有する化合物およびその用途
|
CA2629037A1
(en)
|
2005-11-30 |
2007-06-07 |
Schering Corporation |
Compositions comprising a combination of ccr5 and cxcr4 antagonists
|
PE20070946A1
(es)
|
2006-01-25 |
2007-10-16 |
Smithkline Beecham Corp |
COMPUESTOS DERIVADOS DE IMIDAZO[1,2-a]PIRIDINA COMO MODULADORES DEL RECEPTOR DE QUIMIOQUINA (CXCR4)
|
US20100227880A1
(en)
|
2006-01-25 |
2010-09-09 |
Kristjan Gudmundsson |
Chemical compounds
|
GB0605786D0
(en)
|
2006-03-22 |
2006-05-03 |
Glaxo Group Ltd |
Compounds
|
KR20090013827A
(ko)
|
2006-06-12 |
2009-02-05 |
화이자 프로덕츠 인크. |
Hiv 환자에서 면역 재구성을 증진시키고 기회 감염을 치료하기 위한 ccr5 길항제
|
TWI482772B
(zh)
|
2006-08-21 |
2015-05-01 |
Astrazeneca Ab |
適合口服且包含三唑并[4,5-d]嘧啶衍生物之組合物
|
WO2008141249A1
(en)
|
2007-05-10 |
2008-11-20 |
Acadia Pharmaceuticals Inc. |
Imidazol (1,2-a)pyridines and related compounds with activity at cannabinoid cb2 receptors
|
WO2009026251A1
(en)
|
2007-08-17 |
2009-02-26 |
The General Hospital Corporation |
Detecting ions and measuring ion concentrations
|
JP5690715B2
(ja)
|
2008-03-28 |
2015-03-25 |
アルテイリス・セラピユーテイクス |
ケモカイン受容体調節因子
|
WO2009151910A2
(en)
|
2008-05-25 |
2009-12-17 |
Wyeth |
Combination product of receptor tyrosine kinase inhibitor and fatty acid synthase inhibitor for treating cancer
|
JP2010016628A
(ja)
|
2008-07-03 |
2010-01-21 |
Canon Inc |
画像処理装置及び画像処理方法
|
TW201639852A
(zh)
|
2008-12-09 |
2016-11-16 |
吉李德科學股份有限公司 |
用於製備可用作類鐸受體調節劑之化合物的中間體化合物
|
CN102481261B
(zh)
|
2009-09-28 |
2014-12-31 |
赞布里国际有限公司 |
药物组合物
|
CA2706292A1
(en)
|
2010-05-28 |
2011-11-28 |
Pharmascience Inc. |
A stable pharmaceutical formulation comprising telmisartan and hydrochlorothiazide
|
US20110293521A1
(en)
|
2010-05-28 |
2011-12-01 |
Searete Llc, A Limited Liability Corporation Of The State Of Delaware |
Anti-viral compositions and methods for administration
|
WO2012047339A2
(en)
|
2010-06-28 |
2012-04-12 |
The General Hospital Corporation |
Anti-cxcr4 as a sensitizer to cancer therapeutics
|
GB201017345D0
(en)
|
2010-10-14 |
2010-11-24 |
Proximagen Ltd |
Receptor antagonists
|
WO2012058241A2
(en)
|
2010-10-26 |
2012-05-03 |
University Of South Alabama |
Methods and compositions for ameliorating pancreatic cancer
|
WO2012075362A2
(en)
|
2010-12-03 |
2012-06-07 |
Emory University |
Chemokine cxcr4 receptor modulators and used related thereto
|
EP2648754A4
(en)
|
2010-12-07 |
2016-02-24 |
Philadelphia Health & Educatio |
METHODS OF INHIBITING THE METASTASIS OF CANCER
|
SG190997A1
(en)
|
2010-12-09 |
2013-07-31 |
Univ Pennsylvania |
Use of chimeric antigen receptor-modified t cells to treat cancer
|
EP4215194A1
(en)
|
2011-01-11 |
2023-07-26 |
Dimerix Bioscience Pty Ltd |
Combination therapy
|
RU2638802C2
(ru)
|
2011-05-16 |
2017-12-15 |
Джензим Корпорейшн |
Применение антагонистов cxcr4
|
AR087364A1
(es)
|
2011-07-29 |
2014-03-19 |
Pf Medicament |
Anticuerpo anti-cxcr4 y su uso para la deteccion y dianostico de canceres
|
US8889159B2
(en)
|
2011-11-29 |
2014-11-18 |
Gilead Pharmasset Llc |
Compositions and methods for treating hepatitis C virus
|
US20150004239A1
(en)
|
2012-01-12 |
2015-01-01 |
Gilead Sciences, Inc. |
Pharmaceutical compositions and methods for their preparation
|
AU2013347838A1
(en)
|
2012-11-26 |
2015-06-11 |
Caris Life Sciences Switzerland Holdings Gmbh |
Biomarker compositions and methods
|
US10064826B2
(en)
|
2013-03-15 |
2018-09-04 |
Navinta, Llc |
Direct compression and dry granulation processes for preparing carglumic acid tablets having less impurities than those produced by wet granulation process
|
WO2014197680A1
(en)
|
2013-06-05 |
2014-12-11 |
Salk Institute For Biological Studies |
Vitamin d receptor agonists to treat diseases involving cxcl12 activity
|
WO2015019284A2
(en)
|
2013-08-05 |
2015-02-12 |
Cambridge Enterprise Limited |
Inhibition of cxcr4 signaling in cancer immunotherapy
|
MX2016002185A
(es)
*
|
2013-08-27 |
2016-06-06 |
Gilead Pharmasset Llc |
Formulacion combinada de dos compuestos antivirales.
|
EP3044338B1
(en)
|
2013-09-12 |
2021-11-24 |
Dana-Farber Cancer Institute, Inc. |
Methods for evaluating and treating waldenstrom's macroglobulinemia
|
JP2016540042A
(ja)
|
2013-11-05 |
2016-12-22 |
コグネート バイオサービシズ, インコーポレイテッド |
がんを処置するためのチェックポイント阻害剤および治療薬の組合せ
|
WO2015143092A1
(en)
|
2014-03-18 |
2015-09-24 |
The Research Foundation For The State University Of New York |
Therapeutic agent for treating tumors
|
PT3119397T
(pt)
|
2014-03-19 |
2022-04-11 |
Infinity Pharmaceuticals Inc |
Compostos heterocíclicos para utilização no tratamento de distúrbios mediados por pi3k-gama
|
CA2953177C
(en)
|
2014-06-23 |
2019-07-23 |
Dr. Reddy's Laboratories Ltd. |
Substituted imidazo[1,2-a]pyridine compounds useful for the treatment of pain
|
EP3169341B1
(en)
|
2014-07-16 |
2019-06-05 |
Transgene SA |
Oncolytic virus for expression of immune checkpoint modulators
|
US20180133327A1
(en)
|
2015-03-16 |
2018-05-17 |
Amal Therapeutics Sa |
Cell Penetrating Peptides and Complexes Comprising the Same
|
CA2989144A1
(en)
|
2015-06-12 |
2016-12-15 |
Bristol-Myers Squibb Company |
Treatment of cancer by combined blockade of the pd-1 and cxcr4 signaling pathways
|
US10160761B2
(en)
|
2015-09-14 |
2018-12-25 |
Infinity Pharmaceuticals, Inc. |
Solid forms of isoquinolinones, and process of making, composition comprising, and methods of using the same
|
US10379661B2
(en)
|
2015-09-25 |
2019-08-13 |
Samsung Electronics Co., Ltd. |
Coordinate measuring apparatus and coordinate measuring system having the same
|
EP3389652B1
(en)
|
2015-12-14 |
2022-09-28 |
X4 Pharmaceuticals, Inc. |
Methods for treating cancer
|
JP6864296B2
(ja)
|
2015-12-14 |
2021-04-28 |
エックス4 ファーマシューティカルズ, インコーポレイテッド |
がんを処置する方法
|
ES2935834T3
(es)
|
2015-12-22 |
2023-03-10 |
X4 Pharmaceuticals Inc |
Métodos para tratar enfermedad de inmunodeficiencia
|
WO2017127811A1
(en)
|
2016-01-22 |
2017-07-27 |
X4 Pharmaceuticals, Inc. |
Methods for treating cancer
|
EP3440112A4
(en)
|
2016-04-08 |
2019-10-09 |
X4 Pharmaceuticals, Inc. |
METHOD FOR THE TREATMENT OF CANCER
|
KR102436984B1
(ko)
|
2016-04-14 |
2022-08-26 |
크리에티브이 마이크로테크, 인크. |
암 요법을 위한 치료 결정에서 pd-l1 발현을 사용하는 방법
|
US11332470B2
(en)
|
2016-06-21 |
2022-05-17 |
X4 Pharmaceuticals, Inc. |
CXCR4 inhibitors and uses thereof
|
EP3471726A4
(en)
|
2016-06-21 |
2019-10-09 |
X4 Pharmaceuticals, Inc. |
CXCR4 INHIBITORS AND USES THEREOF
|
JP7054529B2
(ja)
|
2016-06-21 |
2022-04-14 |
エックス4 ファーマシューティカルズ, インコーポレイテッド |
Cxcr4阻害剤およびその使用
|
US20200138804A1
(en)
|
2017-06-21 |
2020-05-07 |
X4 Pharmaceuticals, Inc. |
Methods for treating cancer
|
CA3080821A1
(en)
|
2017-11-07 |
2019-05-16 |
X4 Pharmaceuticals, Inc. |
Cancer biomarkers and methods of use thereof
|
JP2021506838A
(ja)
|
2017-12-19 |
2021-02-22 |
エックス4 ファーマシューティカルズ, インコーポレイテッド |
非環式cxcr4阻害剤およびその使用
|
EP3775877A4
(en)
|
2018-04-13 |
2021-12-22 |
X4 Pharmaceuticals, Inc. |
CANCER SERUM BIOMARKERS AND METHOD OF USE THEREOF
|
US10548889B1
(en)
|
2018-08-31 |
2020-02-04 |
X4 Pharmaceuticals, Inc. |
Compositions of CXCR4 inhibitors and methods of preparation and use
|